Clinical and Experimental Vaccine Research

The Korean Vaccine Society (대한백신학회)
권호 표지
DOI QR코드

DOI QR Code

Comparative analysis of antibody responses to BNT162b2, ChAdOx1, and CoronaVac vaccines in the Albanian population over the pandemic years 2021 to 2022

  • Genc Sulcebe (Academy of Sciences of Albania) ;
  • Margarita Kurti-Prifti (Academy of Sciences of Albania) ;
  • Erkena Shyti (Academy of Sciences of Albania) ;
  • Jonida Dashi-Pasholli (Academy of Sciences of Albania) ;
  • Fabian Cenko (Catholic University "Our Lady of Good Counsel") ;
  • Alban Ylli (University of Medicine of Tirana)
  • Received : 2023.12.19
  • Accepted : 2023.12.28
  • Published : 2024.01.31
Download PDF
⟨ Previous Next ⟩

Abstract

This repeated cross-sectional study with two independent sample populations compared the antibody response to severe acute respiratory syndrome coronavirus 2 vaccines in Albania in July-August 2021 and 2022. In 2021, it found higher anti-spike-1 seropositivity and antibody levels in fully vaccinated individuals, especially with BNT162b2 and ChAdOx1 and to a lesser degree with CoronaVac. By 2022, all single-dose recipients showed high antibody responses, suggesting natural infection-enhanced immunity. The study indicates a significant evolution in the antibody response to different coronavirus disease 2019 vaccines and suggests that a single vaccine dose, coupled with natural infection, might suffice to maintain adequate immunity levels in an endemic scenario.

Keywords

Acknowledgement

The authors acknowledge the essential contributions of Bruna Shiroka, Blerta Berberi, Bujar Mema, Ilirjan Gjyzari, Spartak Caka, and Adelina Selimaj.

References

  1. Barouch DH. COVID-19 vaccines: immunity, variants, boosters. N Engl J Med 2022;387:1011-20.
  2. Watson OJ, Barnsley G, Toor J, Hogan AB, Winskill P, Ghani AC. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. Lancet Infect Dis 2022;22:1293-302.
  3. Zhang G, Tang T, Chen Y, Huang X, Liang T. mRNA vaccines in disease prevention and treatment. Signal Transduct Target Ther 2023;8:365.
  4. Chavda VP, Soni S, Vora LK, Soni S, Khadela A, Ajabiya J. mRNA-based vaccines and therapeutics for COVID-19 and future pandemics. Vaccines (Basel) 2022;10:2150.
  5. Romer D, Jamieson KH. Conspiracy theories as barriers to controlling the spread of COVID-19 in the U.S. Soc Sci Med 2020;263:113356.
  6. Guetl K, Raggam RB, Gary T. Thrombotic complications after COVID-19 vaccination: diagnosis and treatment options. Biomedicines 2022;10:1246.
  7. Saure D, O'Ryan M, Torres JP, Zuniga M, Santelices E, Basso LJ. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study. Lancet Infect Dis 2022;22:56-63.
  8. Voko Z, Kiss Z, Surjan G, et al. Effectiveness and waning of protection with different SARS-CoV-2 primary and booster vaccines during the Delta pandemic wave in 2021 in Hungary (HUN-VE 3 Study). Front Immunol 2022;13:919408.
  9. Dashdorj NJ, Wirz OF, Roltgen K, et al. Direct comparison of antibody responses to four SARS-CoV-2 vaccines in Mongolia. Cell Host Microbe 2021;29:1738-43.
  10. Barin B, Kasap U, Selcuk F, Volkan E, Uluckan O. Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study. Lancet Microbe 2022;3:e274-83.
  11. Ng OT, Marimuthu K, Lim N, et al. Analysis of COVID-19 incidence and severity among adults vaccinated with 2-dose mRNA COVID-19 or inactivated SARS-CoV-2 vaccines with and without boosters in Singapore. JAMA Netw Open 2022;5:e2228900.
  12. Liu Y, Sanchez-Ovando S, Carolan L, et al. Comparative B cell and antibody responses induced by adenoviral vectored and mRNA vaccines against COVID-19. medRxiv [Preprint] 2023 Jun 5. https://doi.org/10.1101/2023.06.02.23290871
  13. Lasrado N, Barouch DH. SARS-CoV-2 hybrid immunity: the best of both worlds. J Infect Dis 2023;228:1311-3.